@entity1030 ( @entity1030 ) exhibits @entity1030 that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an @entity13404 phenotype of @entity1030 would be associated with decreased bronchoreversibility. 544 @entity1 randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. @entity1 underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of @entity2415 by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV(1)) in this @entity1 population is 24% predicted. 22.2% of @entity1 demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few @entity1 (0.37%) had bronchoreversibility on all completed tests. @entity1 who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less @entity2415 . 64% of @entity1 demonstrated large (> or =400 mL) changes in forced vital capacity (FVC). In a severe @entity2415 population, bronchoreversibility as defined by change in FEV(1) is infrequent, varies over time, and is more common in males and those with less severe @entity2415 . Improvements in FVC, however, were demonstrated in the majority of @entity1 .

Prevalence and clinical correlates of bronchoreversibility in severe XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Participants'] @entity13404 :: ('MESH:D041882', 'Disease') :: ['emphysematous'] @entity2415 :: ('MESH:D004646', 'Disease') :: ['emphysema'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['airflow obstruction', 'Chronic obstructive pulmonary disease', 'COPD']
@entity2415 :: (MESH:D004646,Disease) :: ['emphysema']
